Request Access
ARWR
VKTX
ALNY
RCKT
IONS

Biotech Intelligence
for the Buy Side

Competitive landscapes, catalyst tracking, and pipeline analytics — built for investment professionals

Data updated Feb 2, 2026

See What We Track

Real data, updated daily

GLP-1 Landscape

Hot Target
Assets in development 25
Approved 6
Phase 3 7
Disclosed deal value $22.8B
View Report

Upcoming Catalysts

Live
RCKT: KRESLADI PDUFA — Mar 28, 2026
XENE: X-TOLE2 Phase 3 data — Q1 2026
VKTX: Oral VK2735 Phase 2 data — H1 2026
RVMD: RMC-6236 PDAC Phase 3 — H2 2026
View All Catalysts

Recent Deal Activity

2024-25
AZ / CSPC: $4.7B — GLP-1 portfolio
Roche / Zealand: $5.3B — Petrelintide
Pfizer / Metsera: $4.9B — Obesity portfolio
Novo / Akero: $620M — MASH (EFX)
View Deal Tracker

What takes hours, done in minutes

Stop piecing together data from SEC filings, clinicaltrials.gov, and company IR pages

Track every asset targeting GLP-1 across all clinical stages

Complete competitive landscapes with deal terms, trial data, and regulatory milestones

Monitor 60+ biotech pipelines with real-time catalyst updates

PDUFA dates, Phase 3 readouts, and key events automatically tracked

Compare competitive landscapes across therapeutic areas

Side-by-side analysis of clinical data, deal valuations, and market positioning

Satya Bio At A Glance
60+
public biotechs
200+
pipeline assets
$30B+
deal value tracked
Updated Feb 2, 2026
Primary source verified
Companies We Track
ARWRRNAi
ALNYRNAi
VKTXGLP-1
IONSASO
RCKTGene Therapy
NTLACRISPR
RVMDKRAS
MRNAmRNA

Request Access

Currently in private beta with select funds

We'll be in touch within 24 hours